Do analysts recommend ATXI or RDHL?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Avenue Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Redhill Biopharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is ATXI or RDHL more profitable?

Redhill Biopharma's return on equity of 0.00% beat Avenue Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Avenue Therapeutics N/A -471.57% -296.50% Redhill Biopharma N/A N/A N/A

Do analysts prefer ATXI or ALZN?

Alzamend Neuro has a consensus price target of $28.00, suggesting a potential upside of 2,195.08%. Given Alzamend Neuro's stronger consensus rating and higher probable upside, analysts plainly believe Alzamend Neuro is more favorable than Avenue Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Avenue Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Alzamend Neuro 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Which has preferable valuation & earnings, ATXI or ALZN?

Avenue Therapeutics is trading at a lower price-to-earnings ratio than Alzamend Neuro, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Avenue Therapeutics N/A N/A -$10.38M -$0.53 N/A Alzamend Neuro N/A N/A -$4.51M -$2.16 N/A

Is ATXI or ALZN more profitable?

Alzamend Neuro's return on equity of -177.52% beat Avenue Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Avenue Therapeutics N/A -471.57% -296.50% Alzamend Neuro N/A -177.52% -140.41%

Do analysts recommend REVB or ATXI?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Revelation Biosciences 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Avenue Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has stronger valuation and earnings, REVB or ATXI?

Avenue Therapeutics is trading at a lower price-to-earnings ratio than Revelation Biosciences, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Revelation Biosciences N/A N/A -$8.91M -$39.48 N/A Avenue Therapeutics N/A N/A -$10.38M -$0.53 N/A

Is REVB or ATXI more profitable?

Revelation Biosciences' return on equity of -107.65% beat Avenue Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Revelation Biosciences N/A -107.65% -87.98% Avenue Therapeutics N/A -471.57% -296.50%

Do analysts recommend ALBT or ATXI?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Avalon GloboCare 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Avenue Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has better valuation & earnings, ALBT or ATXI?

Avenue Therapeutics is trading at a lower price-to-earnings ratio than Avalon GloboCare, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Avalon GloboCare N/A N/A -$18.26M -$3.51 N/A Avenue Therapeutics N/A N/A -$10.38M -$0.53 N/A

Is ALBT or ATXI more profitable?

Avalon GloboCare's return on equity of 0.00% beat Avenue Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Avalon GloboCare N/A N/A -74.36% Avenue Therapeutics N/A -471.57% -296.50%

Do analysts recommend GRI or ATXI?

GRI Bio currently has a consensus target price of $32.00, suggesting a potential upside of 1,306.59%. Given GRI Bio's stronger consensus rating and higher possible upside, research analysts plainly believe GRI Bio is more favorable than Avenue Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score GRI Bio 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Avenue Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has better valuation & earnings, GRI or ATXI?

Avenue Therapeutics is trading at a lower price-to-earnings ratio than GRI Bio, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio GRI Bio N/A N/A -$11.96M -$74.16 N/A Avenue Therapeutics N/A N/A -$10.38M -$0.53 N/A

Is GRI or ATXI more profitable?

GRI Bio's return on equity of -199.52% beat Avenue Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets GRI Bio N/A -199.52% -143.23% Avenue Therapeutics N/A -471.57% -296.50%

Avenue Therapeutics (ATXI) Competitors

$0.30 -0.02 (-6.25%)

As of 09:46 AM Eastern

Compare

ATXI vs. RDHL, ALZN, REVB, ALBT, and GRI

Should you buy Avenue Therapeutics stock or one of its competitors? MarketBeat compares Avenue Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Avenue Therapeutics include Redhill Biopharma (RDHL), Alzamend Neuro (ALZN), Revelation Biosciences (REVB), Avalon GloboCare (ALBT), and GRI Bio (GRI). These companies are all part of the "pharmaceutical products" industry.

How does Avenue Therapeutics compare to Redhill Biopharma?

Avenue Therapeutics (NASDAQ:ATXI) and Redhill Biopharma (NASDAQ:RDHL) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their profitability, dividends, analyst recommendations, media sentiment, earnings, institutional ownership, risk and valuation.

In the previous week, Redhill Biopharma had 4 more articles in the media than Avenue Therapeutics. MarketBeat recorded 4 mentions for Redhill Biopharma and 0 mentions for Avenue Therapeutics. Redhill Biopharma's average media sentiment score of 0.37 beat Avenue Therapeutics' score of 0.00 indicating that Redhill Biopharma is being referred to more favorably in the news media.

Company	Overall Sentiment
Avenue Therapeutics	Neutral
Redhill Biopharma	Neutral

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Avenue Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Redhill Biopharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Redhill Biopharma has higher revenue and earnings than Avenue Therapeutics. Avenue Therapeutics is trading at a lower price-to-earnings ratio than Redhill Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Avenue Therapeutics	N/A	N/A	-$10.38M	-$0.53	N/A
Redhill Biopharma	$286K	14.52	-$430K	$1.05 thousand	0.00

17.3% of Avenue Therapeutics shares are held by institutional investors. Comparatively, 7.2% of Redhill Biopharma shares are held by institutional investors. 8.6% of Avenue Therapeutics shares are held by insiders. Comparatively, 6.8% of Redhill Biopharma shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Redhill Biopharma's return on equity of 0.00% beat Avenue Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Avenue Therapeutics	N/A	-471.57%	-296.50%
Redhill Biopharma	N/A	N/A	N/A

Avenue Therapeutics has a beta of -0.21, meaning that its share price is 121% less volatile than the broader market. Comparatively, Redhill Biopharma has a beta of 4.98, meaning that its share price is 398% more volatile than the broader market.

Summary

Redhill Biopharma beats Avenue Therapeutics on 9 of the 12 factors compared between the two stocks.

How does Avenue Therapeutics compare to Alzamend Neuro?

Avenue Therapeutics (NASDAQ:ATXI) and Alzamend Neuro (NASDAQ:ALZN) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their analyst recommendations, media sentiment, earnings, dividends, valuation, institutional ownership, profitability and risk.

In the previous week, Alzamend Neuro had 2 more articles in the media than Avenue Therapeutics. MarketBeat recorded 2 mentions for Alzamend Neuro and 0 mentions for Avenue Therapeutics. Alzamend Neuro's average media sentiment score of 0.93 beat Avenue Therapeutics' score of 0.00 indicating that Alzamend Neuro is being referred to more favorably in the news media.

Company	Overall Sentiment
Avenue Therapeutics	Neutral
Alzamend Neuro	Positive

17.3% of Avenue Therapeutics shares are held by institutional investors. Comparatively, 49.6% of Alzamend Neuro shares are held by institutional investors. 8.6% of Avenue Therapeutics shares are held by insiders. Comparatively, 1.4% of Alzamend Neuro shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Alzamend Neuro's return on equity of -177.52% beat Avenue Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Avenue Therapeutics	N/A	-471.57%	-296.50%
Alzamend Neuro	N/A	-177.52%	-140.41%

Avenue Therapeutics is trading at a lower price-to-earnings ratio than Alzamend Neuro, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Avenue Therapeutics	N/A	N/A	-$10.38M	-$0.53	N/A
Alzamend Neuro	N/A	N/A	-$4.51M	-$2.16	N/A

Alzamend Neuro has a consensus price target of $28.00, suggesting a potential upside of 2,195.08%. Given Alzamend Neuro's stronger consensus rating and higher probable upside, analysts plainly believe Alzamend Neuro is more favorable than Avenue Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Avenue Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Alzamend Neuro	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Avenue Therapeutics has a beta of -0.21, suggesting that its share price is 121% less volatile than the broader market. Comparatively, Alzamend Neuro has a beta of 0.16, suggesting that its share price is 84% less volatile than the broader market.

Summary

Alzamend Neuro beats Avenue Therapeutics on 10 of the 13 factors compared between the two stocks.

How does Avenue Therapeutics compare to Revelation Biosciences?

Revelation Biosciences (NASDAQ:REVB) and Avenue Therapeutics (NASDAQ:ATXI) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their media sentiment, analyst recommendations, profitability, valuation, institutional ownership, dividends, risk and earnings.

Revelation Biosciences has a beta of -0.09, suggesting that its stock price is 109% less volatile than the broader market. Comparatively, Avenue Therapeutics has a beta of -0.21, suggesting that its stock price is 121% less volatile than the broader market.

Avenue Therapeutics is trading at a lower price-to-earnings ratio than Revelation Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Revelation Biosciences	N/A	N/A	-$8.91M	-$39.48	N/A
Avenue Therapeutics	N/A	N/A	-$10.38M	-$0.53	N/A

Revelation Biosciences' return on equity of -107.65% beat Avenue Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Revelation Biosciences	N/A	-107.65%	-87.98%
Avenue Therapeutics	N/A	-471.57%	-296.50%

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Revelation Biosciences	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Avenue Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

12.8% of Revelation Biosciences shares are owned by institutional investors. Comparatively, 17.3% of Avenue Therapeutics shares are owned by institutional investors. 4.8% of Revelation Biosciences shares are owned by insiders. Comparatively, 8.6% of Avenue Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Revelation Biosciences had 1 more articles in the media than Avenue Therapeutics. MarketBeat recorded 1 mentions for Revelation Biosciences and 0 mentions for Avenue Therapeutics. Revelation Biosciences' average media sentiment score of 1.89 beat Avenue Therapeutics' score of 0.00 indicating that Revelation Biosciences is being referred to more favorably in the media.

Company	Overall Sentiment
Revelation Biosciences	Very Positive
Avenue Therapeutics	Neutral

Summary

Revelation Biosciences beats Avenue Therapeutics on 7 of the 11 factors compared between the two stocks.

How does Avenue Therapeutics compare to Avalon GloboCare?

Avalon GloboCare (NASDAQ:ALBT) and Avenue Therapeutics (NASDAQ:ATXI) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their earnings, analyst recommendations, risk, institutional ownership, media sentiment, valuation, dividends and profitability.

Avalon GloboCare has a beta of -0.06, meaning that its stock price is 106% less volatile than the broader market. Comparatively, Avenue Therapeutics has a beta of -0.21, meaning that its stock price is 121% less volatile than the broader market.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Avalon GloboCare	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Avenue Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

In the previous week, Avalon GloboCare had 1 more articles in the media than Avenue Therapeutics. MarketBeat recorded 1 mentions for Avalon GloboCare and 0 mentions for Avenue Therapeutics. Avalon GloboCare's average media sentiment score of 1.87 beat Avenue Therapeutics' score of 0.00 indicating that Avalon GloboCare is being referred to more favorably in the media.

Company	Overall Sentiment
Avalon GloboCare	Very Positive
Avenue Therapeutics	Neutral

Avenue Therapeutics is trading at a lower price-to-earnings ratio than Avalon GloboCare, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Avalon GloboCare	N/A	N/A	-$18.26M	-$3.51	N/A
Avenue Therapeutics	N/A	N/A	-$10.38M	-$0.53	N/A

1.4% of Avalon GloboCare shares are held by institutional investors. Comparatively, 17.3% of Avenue Therapeutics shares are held by institutional investors. 24.2% of Avalon GloboCare shares are held by insiders. Comparatively, 8.6% of Avenue Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Avalon GloboCare's return on equity of 0.00% beat Avenue Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Avalon GloboCare	N/A	N/A	-74.36%
Avenue Therapeutics	N/A	-471.57%	-296.50%

Summary

Avalon GloboCare beats Avenue Therapeutics on 7 of the 11 factors compared between the two stocks.

How does Avenue Therapeutics compare to GRI Bio?

GRI Bio (NASDAQ:GRI) and Avenue Therapeutics (NASDAQ:ATXI) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, dividends, earnings, media sentiment, analyst recommendations, profitability, institutional ownership and risk.

34.0% of GRI Bio shares are held by institutional investors. Comparatively, 17.3% of Avenue Therapeutics shares are held by institutional investors. 8.7% of GRI Bio shares are held by company insiders. Comparatively, 8.6% of Avenue Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

GRI Bio has a beta of -1.17, meaning that its share price is 217% less volatile than the broader market. Comparatively, Avenue Therapeutics has a beta of -0.21, meaning that its share price is 121% less volatile than the broader market.

Avenue Therapeutics is trading at a lower price-to-earnings ratio than GRI Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
GRI Bio	N/A	N/A	-$11.96M	-$74.16	N/A
Avenue Therapeutics	N/A	N/A	-$10.38M	-$0.53	N/A

GRI Bio currently has a consensus target price of $32.00, suggesting a potential upside of 1,306.59%. Given GRI Bio's stronger consensus rating and higher possible upside, research analysts plainly believe GRI Bio is more favorable than Avenue Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
GRI Bio	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Avenue Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

GRI Bio's return on equity of -199.52% beat Avenue Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
GRI Bio	N/A	-199.52%	-143.23%
Avenue Therapeutics	N/A	-471.57%	-296.50%

In the previous week, GRI Bio had 1 more articles in the media than Avenue Therapeutics. MarketBeat recorded 1 mentions for GRI Bio and 0 mentions for Avenue Therapeutics. GRI Bio's average media sentiment score of 1.87 beat Avenue Therapeutics' score of 0.00 indicating that GRI Bio is being referred to more favorably in the media.

Company	Overall Sentiment
GRI Bio	Very Positive
Avenue Therapeutics	Neutral

Summary

GRI Bio beats Avenue Therapeutics on 9 of the 13 factors compared between the two stocks.

Get Avenue Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ATXI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ATXI vs. The Competition

Export

Metric	Avenue Therapeutics	Pharmaceutical Industry	Medical Sector	NASDAQ Exchange
Market Cap	$988K	$968.72M	$6.48B	$12.36B
Dividend Yield	N/A	4.84%	2.67%	5.66%
P/E Ratio	0.02	1.46	23.95	24.60
Price / Sales	N/A	123.53	536.37	171.61
Price / Cash	N/A	20.06	27.48	37.92
Price / Book	0.16	8.01	10.44	6.77
Net Income	-$10.38M	-$4.88M	$3.56B	$337.32M
7 Day Performance	-3.23%	2.73%	0.83%	2.06%
1 Month Performance	N/A	2.23%	1.78%	3.93%
1 Year Performance	44.09%	46.76%	25.59%	32.29%

Avenue Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ATXI Avenue Therapeutics	N/A	$0.30 -6.3%	N/A	+53.7%	$988K	N/A	0.02	4	Gap Down
RDHL Redhill Biopharma	1.0174 of 5 stars	$0.91 +3.4%	N/A	-53.7%	$4.73M	$290K	0.00	210
ALZN Alzamend Neuro	3.831 of 5 stars	$1.20 +3.0%	$28.00 +2,243.1%	-62.7%	$4.48M	N/A	N/A	4	Positive News
REVB Revelation Biosciences	1.4128 of 5 stars	$1.04 +0.2%	N/A	-89.5%	$4.09M	N/A	N/A	10	Positive News Gap Up
ALBT Avalon GloboCare	1.0556 of 5 stars	$0.34 -2.6%	N/A	-89.5%	$4.09M	$1.26M	N/A	5

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ATXI) was last updated on 6/15/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Avenue Therapeutics (ATXI) Competitors

ATXI vs. RDHL, ALZN, REVB, ALBT, and GRI

How does Avenue Therapeutics compare to Redhill Biopharma?

Summary

How does Avenue Therapeutics compare to Alzamend Neuro?

Summary

How does Avenue Therapeutics compare to Revelation Biosciences?

Summary

How does Avenue Therapeutics compare to Avalon GloboCare?

Summary

How does Avenue Therapeutics compare to GRI Bio?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ATXI vs. The Competition

Avenue Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Avenue Therapeutics (ATXI) Competitors

ATXI vs. RDHL, ALZN, REVB, ALBT, and GRI

How does Avenue Therapeutics compare to Redhill Biopharma?

Does the media refer more to ATXI or RDHL?

Do analysts recommend ATXI or RDHL?

Which has stronger valuation & earnings, ATXI or RDHL?

Do institutionals and insiders hold more shares of ATXI or RDHL?

Is ATXI or RDHL more profitable?

Which has more risk and volatility, ATXI or RDHL?

Summary

How does Avenue Therapeutics compare to Alzamend Neuro?

Does the media favor ATXI or ALZN?

Do institutionals & insiders hold more shares of ATXI or ALZN?

Is ATXI or ALZN more profitable?

Which has preferable valuation & earnings, ATXI or ALZN?

Do analysts prefer ATXI or ALZN?

Which has more risk & volatility, ATXI or ALZN?

Summary

How does Avenue Therapeutics compare to Revelation Biosciences?

Which has more risk and volatility, REVB or ATXI?

Which has stronger valuation and earnings, REVB or ATXI?

Is REVB or ATXI more profitable?

Do analysts recommend REVB or ATXI?

Do institutionals & insiders hold more shares of REVB or ATXI?

Does the media refer more to REVB or ATXI?

Summary

How does Avenue Therapeutics compare to Avalon GloboCare?

Which has more volatility & risk, ALBT or ATXI?

Do analysts recommend ALBT or ATXI?

Does the media prefer ALBT or ATXI?

Which has better valuation & earnings, ALBT or ATXI?

Do institutionals & insiders hold more shares of ALBT or ATXI?

Is ALBT or ATXI more profitable?

Summary

How does Avenue Therapeutics compare to GRI Bio?

Do institutionals and insiders hold more shares of GRI or ATXI?

Which has more risk & volatility, GRI or ATXI?

Which has better valuation & earnings, GRI or ATXI?

Do analysts recommend GRI or ATXI?

Is GRI or ATXI more profitable?

Does the media prefer GRI or ATXI?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ATXI vs. The Competition

Avenue Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools